Collumbotai Bio-B (06990) rose more than 9% in the intraday period. As of press release, it was up 6.44% to HK$147.2, with a turnover of HK$21.7879 million.
The Zhitong Finance App learned that Columbite Biotech (06990) rose more than 9% in the intraday period. As of press release, it had risen 6.44% to HK$147.2, with a turnover of HK$21.7879 million.
According to the news, Collumbotai Biotech announced that it will reveal the latest efficacy and safety results of the Phase 2 study on patients with advanced non-small cell lung cancer (NSCLC) who have previously been treated with advanced non-small cell lung cancer (NSCLC) during a poster presentation session at the 2024 American Association for Cancer Research (AACR) annual meeting to be held in San Diego, California, USA from April 5 to 10.
Additionally, the company will announce the preliminary efficacy and safety results of its phase 2 study of anti-TROP2ADC lucansastuzumab (sAC-TMT) in patients with advanced gastric cancer or esophagogastric junction (GEJ) cancer who have previously been treated.